Physician
Mcgivney, Randall
Mcgivney, Randall was paid $4.13M by Medicaid between Jan 2018 and Dec 2024, across 192 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 9.2% of everything it billed.
33Billing provider infoMCGIVNEY, RANDALL
OAK PARK, IL 60302
OAK PARK, IL 60302
33aNPI1710917836assigned 07/04/2006
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$4.13M
24GClaims645,112
24DCodes billed192
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Illinois
Rank by total paid#14 of 398
Median peer was paid$66K
This provider vs. median63×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 93,615 | $437K | |
| 2019 | 115,191 | $589K | |
| 2020 | 103,136 | $683K | |
| 2021 | 110,534 | $923K | |
| 2022 | 94,278 | $705K | |
| 2023 | 59,138 | $337K | |
| 2024incomplete | 69,220 | $460K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 9.2% | 15,060 | 11,009 | $379K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 8.2% | 9,181 | 7,773 | $341K |
| 80053 | Comprehensive metabolic panel | 6.6% | 53,898 | 35,644 | $273K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 5.1% | 8,915 | 7,540 | $210K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.8% | 68,785 | 41,175 | $200K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 3.9% | 3,265 | 2,972 | $160K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 3.2% | 5,355 | 4,423 | $131K |
| 80048 | Basic metabolic panel (calcium, ionized) | 3.1% | 31,153 | 14,586 | $128K |
| 88307 | 3.0% | 2,067 | 1,879 | $126K | |
| 83735 | 2.8% | 31,837 | 15,111 | $114K | |
| 80185 | 2.2% | 14,135 | 7,616 | $92K | |
| 84484 | 2.2% | 20,727 | 14,770 | $91K |
180 more codes
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.2% | 4,419 | $90K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.1% | 3,958 | $85K |
| 82803 | 2.0% | 8,480 | $84K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.0% | 6,198 | $84K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.7% | 1,384 | $69K |
| 87040 | 1.6% | 6,140 | $68K | |
| 83880 | 1.6% | 6,012 | $65K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.5% | 7,376 | $61K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.2% | 10,012 | $52K |
| 85027 | 1.2% | 17,244 | $50K | |
| 86762 | 1.2% | 11,814 | $50K | |
| 83605 | 1.2% | 8,785 | $50K | |
| 83690 | 1.2% | 14,526 | $49K | |
| 88341 | 1.2% | 2,418 | $48K | |
| 82962 | 1.0% | 28,792 | $43K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.0% | 1,407 | $42K |
| 88342 | <1% | 3,169 | $39K | |
| 86480 | <1% | 1,365 | $35K | |
| 85730 | <1% | 8,992 | $32K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,370 | $30K |
| 84702 | <1% | 6,472 | $29K | |
| 80074 | <1% | 1,614 | $29K | |
| 88304 | <1% | 1,648 | $28K | |
| 84100 | <1% | 13,947 | $27K | |
| 86850 | <1% | 7,648 | $22K | |
| 86901 | <1% | 9,999 | $22K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 640 | $22K |
| 85610 | <1% | 10,307 | $22K | |
| 81003 | <1% | 19,893 | $19K | |
| 86022 | <1% | 1,921 | $18K | |
| 80061 | Lipid panel | <1% | 6,268 | $18K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,936 | $17K |
| 86225 | <1% | 2,910 | $17K | |
| 86900 | <1% | 10,002 | $17K | |
| 80202 | <1% | 2,197 | $16K | |
| 87186 | <1% | 2,877 | $16K | |
| 81025 | <1% | 5,948 | $16K | |
| 81001 | <1% | 8,992 | $14K | |
| 87081 | <1% | 3,912 | $13K | |
| 87430 | <1% | 1,506 | $11K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 982 | $11K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 71 | $11K |
| 89051 | <1% | 3,206 | $11K | |
| 85379 | <1% | 2,875 | $11K | |
| 87480 | <1% | 1,100 | $11K | |
| 86780 | <1% | 1,087 | $9K | |
| 82607 | <1% | 1,443 | $8K | |
| 87102 | <1% | 2,630 | $8K | |
| 82728 | <1% | 2,023 | $8K | |
| 84439 | <1% | 1,811 | $8K | |
| 82570 | <1% | 3,732 | $7K | |
| 81241 | <1% | 956 | $7K | |
| 87070 | <1% | 2,239 | $7K | |
| 82550 | <1% | 2,790 | $7K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,704 | $7K |
| 86920 | <1% | 1,599 | $6K | |
| 83550 | <1% | 1,619 | $6K | |
| 88141 | <1% | 524 | $6K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 176 | $6K |
| 86160 | <1% | 1,266 | $6K | |
| 87631 | <1% | 114 | $6K | |
| 83540 | <1% | 1,793 | $6K | |
| 82784 | <1% | 1,204 | $6K | |
| 82746 | <1% | 1,006 | $6K | |
| 87510 | <1% | 494 | $6K | |
| 86304 | <1% | 476 | $5K | |
| 87493 | <1% | 227 | $5K | |
| 86592 | <1% | 2,649 | $5K | |
| 86140 | <1% | 2,163 | $5K | |
| 87340 | <1% | 950 | $5K | |
| 80076 | <1% | 1,594 | $5K | |
| 87116 | <1% | 771 | $5K | |
| 87077 | <1% | 1,967 | $5K | |
| 87205 | <1% | 2,192 | $4K | |
| 82247 | <1% | 1,994 | $4K | |
| 87807 | <1% | 860 | $4K | |
| 82330 | <1% | 583 | $4K | |
| 82248 | <1% | 2,260 | $4K | |
| 84145 | <1% | 343 | $4K | |
| 87184 | <1% | 817 | $4K | |
| 87641 | <1% | 179 | $4K | |
| 87660 | <1% | 527 | $4K | |
| 88312 | <1% | 205 | $4K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 74 | $3K |
| 84295 | <1% | 1,590 | $3K | |
| 81015 | <1% | 7,470 | $3K | |
| 80164 | <1% | 670 | $3K | |
| 85007 | <1% | 2,190 | $3K | |
| 85652 | <1% | 2,121 | $3K | |
| 82140 | <1% | 579 | $3K | |
| 87420 | <1% | 334 | $3K | |
| 85018 | <1% | 2,490 | $2K | |
| 86803 | <1% | 382 | $2K | |
| 83615 | <1% | 946 | $2K | |
| 84030 | <1% | 915 | $2K | |
| 86787 | <1% | 405 | $2K | |
| 87449 | <1% | 180 | $2K | |
| 82010 | <1% | 1,013 | $2K | |
| 86704 | <1% | 277 | $2K | |
| 88313 | <1% | 208 | $2K | |
| 85008 | <1% | 1,527 | $2K | |
| 83655 | <1% | 358 | $2K | |
| 86141 | <1% | 226 | $2K | |
| 87075 | <1% | 272 | $2K | |
| 84600 | <1% | 878 | $2K | |
| 82805 | <1% | 323 | $2K | |
| 87486 | <1% | 81 | $2K | |
| 87280 | <1% | 235 | $2K | |
| 80143 | <1% | 156 | $2K | |
| 87088 | <1% | 312 | $2K | |
| 80179 | <1% | 151 | $2K | |
| 81240 | <1% | 196 | $2K | |
| 80170 | <1% | 273 | $2K | |
| 84156 | <1% | 1,436 | $2K | |
| 86880 | <1% | 516 | $2K | |
| 88311 | <1% | 321 | $2K | |
| 84466 | <1% | 356 | $2K | |
| 87581 | <1% | 72 | $2K | |
| 88112 | <1% | 82 | $1K | |
| 86921 | <1% | 290 | $1K | |
| 85014 | <1% | 1,465 | $1K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 108 | $1K |
| 84545 | <1% | 645 | $1K | |
| 86038 | <1% | 172 | $1K | |
| 88360 | <1% | 27 | $1K | |
| 84403 | <1% | 106 | $1K | |
| 82105 | <1% | 149 | $1K | |
| 83001 | <1% | 124 | $1K | |
| 84510 | <1% | 203 | $915.20 | |
| 84153 | <1% | 138 | $819.35 | |
| 82043 | <1% | 421 | $783.09 | |
| 82950 | <1% | 387 | $714.45 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 30 | $687.00 |
| 84146 | <1% | 111 | $671.00 | |
| 86769 | <1% | 27 | $653.11 | |
| 87147 | <1% | 342 | $643.58 | |
| 87210 | <1% | 265 | $618.05 | |
| 84300 | <1% | 255 | $538.36 | |
| 84132 | <1% | 546 | $519.70 | |
| 84550 | <1% | 300 | $476.72 | |
| 83013 | <1% | 54 | $407.64 | |
| 82948 | <1% | 96 | $286.90 | |
| 82150 | <1% | 73 | $239.73 | |
| 86593 | <1% | 121 | $234.00 | |
| 82565 | <1% | 108 | $229.50 | |
| 88302 | <1% | 14 | $225.02 | |
| 88104 | <1% | 14 | $214.80 | |
| 84478 | <1% | 152 | $205.22 | |
| 86706 | <1% | 30 | $203.00 | |
| 87045 | <1% | 34 | $202.95 | |
| 84402 | <1% | 23 | $201.74 | |
| 85045 | <1% | 160 | $198.62 | |
| 82495 | <1% | 31 | $194.59 | |
| 86235 | <1% | 23 | $177.00 | |
| 82670 | <1% | 27 | $169.82 | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 18 | $163.20 |
| 86696 | <1% | 12 | $161.60 | |
| 85384 | <1% | 53 | $160.77 | |
| 87806 | <1% | 17 | $157.28 | |
| 82270 | <1% | 123 | $154.91 | |
| 84480 | <1% | 34 | $143.40 | |
| 87206 | <1% | 63 | $138.60 | |
| 84436 | <1% | 44 | $131.04 | |
| 85378 | <1% | 35 | $122.15 | |
| 87209 | <1% | 14 | $105.42 | |
| 84450 | <1% | 47 | $100.40 | |
| 82951 | <1% | 15 | $85.90 | |
| 84460 | <1% | 47 | $81.79 | |
| 83002 | <1% | 14 | $62.02 | |
| 80050 | General health panel | <1% | 1,474 | $53.25 |
| 82103 | <1% | 12 | $53.16 | |
| 87177 | <1% | 14 | $50.40 | |
| 84520 | <1% | 32 | $48.25 | |
| 84540 | <1% | 22 | $47.52 | |
| 83930 | <1% | 19 | $44.27 | |
| 87076 | <1% | 205 | $33.32 | |
| 82952 | <1% | 15 | $26.06 | |
| 87106 | 0% | 70 | $0.00 | |
| 80320 | 0% | 665 | $0.00 | |
| 80329 | 0% | 285 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.